RxGen PrimaTox, Inc And BioTrove, Inc. Announce Collaboration

SANTA FE, N.M. & WOBURN, Mass.--(BUSINESS WIRE)--Jan. 30, 2006--Today BioTrove and RxGen PrimaTox Inc. (RxP) announced a collaboration to provide gene expression and SNP assays designed to work equally well in primates and humans, thus bridging the gap between pre-clinical and clinical drug safety analysis. RxP’s Tox-Optimum(TM) gene expression assays include the most toxicologically relevant genes, probes for which have been optimized to work in samples from either humans or non-human primates. The Tox-Optimum(TM) assays have been designed to work specifically and exclusively on BioTrove’s OpenArray(TM) platform, which allows simultaneous quantitative analysis of several thousand genes by quantitative PCR. RxP will provide the Tox-Optimum(TM) assays as either stand-alone products, or as a service that utilizes RxP’s unique toxicological resources. BioTrove will provide the OpenArray(TM) platform and will manufacture the Tox-Optimum(TM) assays to RxP’s specifications. RxP will also provide similar assays that measure expression of thousands of other genes highly relevant to drug efficacy that have also been optimized for use in either primates or humans.